Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMYHBKN)

Drug Name
Exenatide Drug Info
Synonyms Exenatide Synthetic; AC 2993 LAR; Ex4 peptide; Byetta (TN); Exendin 4 (Heloderma suspectum); Extendin-4; L-Serinamide
Indication
Disease Entry ICD 11 Status REF
Inflammation 1A00-CA43.1 Approved [1]
Non-insulin dependent diabetes 5A11 Approved [1]
Type-1/2 diabetes 5A10-5A11 Approved [1]
Type-2 diabetes 5A11 Approved [2]
Cardiovascular disease BA00-BE2Z Phase 3 [3]
Therapeutic Class
Hypoglycemic Agents
Cross-matching ID
PubChem CID
45588096
CAS Number
CAS 141758-74-9
TTD Drug ID
DMYHBKN
INTEDE Drug ID
DR0676

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Glucagon-like peptide 1 receptor (GLP1R) TTVIMDE GLP1R_HUMAN Binder [4]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID Highest Status REF
Dipeptidyl peptidase IV (DPP4) DEKZQY6 DPP4_HUMAN Approved [5]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Glucagon-like peptide 1 receptor (GLP1R) DTT GLP1R 2 2.848 3.472 2.963
Dipeptidyl peptidase IV (DPP4) DME DPP4 4.995 4.926 7.852 8.358
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Inflammation
ICD Disease Classification 1A00-CA43.1
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Glucagon-like peptide 1 receptor (GLP1R) DTT GLP1R 1.25E-01 0.17 1.26
Dipeptidyl peptidase IV (DPP4) DME DPP4 9.54E-01 -2.74E-01 -1.85E+00
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Exenatide FDA Label
2 Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Improved glycemic control and reduction of cardiometabolic risk factors in subjects with type 2 diabetes and metabolic syndrome treated with exenatide in a clinical practice setting. Diabetes TechnolTher. 2009 Jun;11(6):353-9.
5 In vitro metabolic stability of exendin-4: pharmacokinetics and identification of cleavage products. PLoS One. 2015 Feb 27;10(2):e0116805.